Navamedic ASA Financial report for Q3 2012
Navamedic continued its strong sales growth also in the third quarter of 2012. The quarter gave a sales growth of 21 per cent compared to the same period last year, while revenues grew by 23 per cent in the first nine months of the year. Navamedic has delivered positive EBITDA in four consecutive quarters and a positive EBITDA for the full year 2012 is secured.
| (in NOK '000) | Q3 2012 | Q3 2011 | YTD 2012 | YTD 2011 | FY 2011 |
| Revenues | 20 571 | 17 025 | 63 860 | 51 992 | 71 299 |
| Gross Profit | 8 913 | 7 178 | 26 391 | 21 004 | 29 272 |
| Gross margin | 43 % | 42 % | 41 % | 40 % | 41 % |
| EBITDA | 570 | -863 | 1 065 | -2 942 | -2 639 |
| EBIT | -988 | -2 557 | -3 609 | -8 032 | -9 359 |
For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.
Navamedic ASA is a Norwegian pharmaceutical products company. Through its subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of nutrition and pharmaceutical products in the Nordic markets. Navamedic is currently building up a generic pharmaceutical business for the Nordic, Dutch and Belgian markets based on its partnership with Aspen Healthcare of South Africa.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
The full report with tables and the presentation can be downloaded from the following links: